KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Deferred Tax Liability: 2015-2019

Historic Non-Current Deferred Tax Liability for Arbutus Biopharma (ABUS) over the last 4 years, with Jun 2019 value amounting to $12.7 million.

  • Arbutus Biopharma's Non-Current Deferred Tax Liability fell 25.27% to $12.7 million in Q2 2019 from the same period last year, while for Jun 2019 it was $12.7 million, marking a year-over-year decrease of 25.27%. This contributed to the annual value of $12.7 million for FY2018, which is 25.27% down from last year.
  • As of Q2 2019, Arbutus Biopharma's Non-Current Deferred Tax Liability stood at $12.7 million, which was down 0.00% from $12.7 million recorded in Q1 2019.
  • Arbutus Biopharma's Non-Current Deferred Tax Liability's 5-year high stood at $156.0 million during Q2 2015, with a 5-year trough of $12.7 million in Q3 2018.
  • In the last 3 years, Arbutus Biopharma's Non-Current Deferred Tax Liability had a median value of $16.9 million in 2018 and averaged $22.5 million.
  • Data for Arbutus Biopharma's Non-Current Deferred Tax Liability shows a maximum YoY plummeted of 71.80% (in 2016) over the last 5 years.
  • Over the past 5 years, Arbutus Biopharma's Non-Current Deferred Tax Liability (Quarterly) stood at $146.3 million in 2015, then slumped by 71.80% to $41.3 million in 2016, then crashed by 58.94% to $16.9 million in 2017, then decreased by 25.27% to $12.7 million in 2018, then dropped by 25.27% to $12.7 million in 2019.
  • Its Non-Current Deferred Tax Liability was $12.7 million in Q2 2019, compared to $12.7 million in Q1 2019 and $12.7 million in Q4 2018.